MedTrace Logo

Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)

NCT05182970 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5160

Last updated 2024-04-02

No results posted yet for this study

Summary

Prediabetes is associated to an increased risk of cardiovascular disease and mortality. Although metformin can delay progression to diabetes there is a lack of RCTs evaluating the effect of metformin on cardiovascular outcomes. MIMET aims to investigate if addition of metformin to standard care has effects on the occurrence of cardiovascular events after acute myocardial infarction in patients with newly detected prediabetes (identified by oral glucose tolerance test, HbA1c or fasting glucose levels).

Conditions

  • PreDiabetes
  • Acute Myocardial Infarction
  • Non ST Elevation Myocardial Infarction
  • ST Elevation Myocardial Infarction

Interventions

DRUG

Metformin

Individualised target dose of 2000 mg daily depending on tolerability.

Sponsors & Collaborators

  • Capio Sankt Görans Hospital

    collaborator OTHER

  • Uppsala University

    collaborator OTHER

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Anna Norhammar, MD, Prof. · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-02
Primary Completion
2026-05-31
Completion
2026-05-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05182970 on ClinicalTrials.gov